Primer on Medical Genomics Part XII: Pharmacogenomics -- General Principles With Cancer as a Model

Goetz, Matthew P.; Ames, Matthew M.; Weinshilboum, Richard M.
March 2004
Mayo Clinic Proceedings;Mar2004, Vol. 79 Issue 3, p376
Academic Journal
The Human Genome Project has resulted in a new era in the field of pharmacogenetics in which researchers are rapidly discovering new genetic variation, which may help to explain interindividual variability in drug efficacy and toxicity. Pharmacogenetics is the study of the role of genetic inheritance in individual variation in drug response and toxicity. With the convergence of advances in pharmacogenetics and human genomics, the field of pharmacogenomics has emerged during the past decade. Pharmacogenomics is used to refer to the study of the relationship between specific DNA-sequence variation and drug effect. In few other disciplines of medicine are the clinical examples of pharmacogenetics more striking than in oncology. In this field, treatment of patients with cancer is accomplished primarily through the use of chemotherapeutic drugs that have narrow therapeutic indexes, ie, the difference between the toxic and therapeutic dose is relatively small. In this review, we discuss several selected, clinically relevant examples of ways in which sequence variation in genes that encode drug enzymes, transporters, and drug targets can alter the efficacy and/or adverse-effect profile of "standard" doses of chemotherapeutic drugs. Additionally, we discuss some of the ways in which physicians are currently applying this knowledge in the treatment of patients with cancer.


Related Articles

  • In Silico Drug Discovery: Solving the “Target-rich and Lead-poor” Imbalance Using the Genome-to-drug-lead Paradigm. Pang, Y. P. // Clinical Pharmacology & Therapeutics;Jan2007, Vol. 81 Issue 1, p30 

    Advances in genomics, proteomics, and structural genomics have identified a large number of protein targets. Virtual screening has gained popularity in identifying drug leads by computationally screening large numbers of chemicals against experimentally determined protein targets. In that...

  • Validating cancer drug targets. Benson, John D.; Chen, Ying-Nan P.; Cornell-Kennon, Susan A.; Dorsch, Marion; Sunkyu im; Leszczyniecka, Magdalena; Sellers, William R.; Lengauer, Christoph // Nature;5/25/2006, Vol. 441 Issue 7092, p451 

    A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as ‘validated’ before investing in a...

  • Novel Molecular Targets in Cancer Chemotherapy Waiting for Discovery. Kunick, Conrad // Current Medicinal Chemistry - Anti-Cancer Agents;Sep2004, Vol. 4 Issue 5, p421 

    Despite a number of advances in the past decades the medicinal cancer therapy is hampered by problems of severe unwanted side effects and the development of resistances. Many established anti-cancer drugs are directed toward targets that are not specific for cancer but are essential biochemical...

  • Therapy: Special delivery. McCarthy, Nicola // Nature Reviews Cancer;Aug2009, Vol. 9 Issue 8, p534 

    The article offers information on the research that could reduce cancer therapy side effects by specifically targeting drugs to the tumor. According to researchers in Great Britain, the utilization of tumor-targeted minicells could achieve such objective. Research results indicated that...

  • A Phase II Study of a Daily x 4 Schedule of Vinorelbine Plus Cisplatin for Advanced Non-small Cell Lung Cancer. Han, Ji-Youn; Kim, Ki Won; Kim, Jung Ah; Kang, Jin Hyung; Jin, Jong-Youl; Hong, Young Seon; Park, Suk Young; Song, Jung-Sup; Park, Jong Won; Kim, Hoon-Kyo; Lee, Kyung Shik; Choi, Byung Gil // Japanese Journal of Clinical Oncology;Oct2000, Vol. 30 Issue 10 

    Explores the possibility of increasing the dose of advanced non-small cell lung cancer drug, vinorelbine on a four times daily schedule to determine whether dose intensity affects response to the drug. Overall response rate; Toxicity of myelosuppression; Comparable therapeutic activity of the...

  • IDMap: facilitating the detection of potential leads with therapeutic targets. Soyang Ha; Young-Ju Seo; Min-Seok Kwon; Byung-Ha Chang; Cheol-Kyu Han; Jeong-Hyeok Yoon // Bioinformatics;Jun2008, Vol. 24 Issue 11, p1413 

    Summary: Pharmaceutical industry has been striving to reduce the costs of drug development and increase productivity. Among the many different attempts, drug repositioning (retargeting existing drugs) comes into the spotlight because of its financial efficiency. We introduce IDMap which predicts...

  • Computational inhibitor design against malaria plasmepsins. Bjelic, S.; Nervall, M.; Gutiérrez-de-Terán, H.; Ersmark, K.; Hallberg, A.; Åqvist, J. // Cellular & Molecular Life Sciences;Sep2007, Vol. 64 Issue 17, p2285 

    Plasmepsins are aspartic proteases involved in the degradation of the host cell hemoglobin that is used as a food source by the malaria parasite. Plasmepsins are highly promising as drug targets, especially when combined with the inhibition of falcipains that are also involved in hemoglobin...

  • Progress in Thioaptamer Development. Xianbin Yang; Gorenstein, David G. // Current Drug Targets;Nov2004, Vol. 5 Issue 8, p705 

    Thioaptamers are thiophosphate ester modified nucleic acids that are isolated via in vitro or bead-based thioaptamer selection against a target molecule such as a protein. Thioaptamers offer advantages over traditional aptamers in their enhanced affinity and specificity and higher stability,...

  • Development and application of targeted therapeutic protein conjugates. Maksimenko, A. // Russian Journal of General Chemistry;Feb2014, Vol. 84 Issue 2, p357 

    The present review considers therapeutic protein conjugates (bioconjugates) in terms of the concept of drug targeting delivery in the body.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics